TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06385925: A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Sponsor: Tyligand Pharmaceuticals (Suzhou) Limited · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 440 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06385925 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06385925 Rescue Dossier →